news

Artificial Intelligence system to help detect skin cancer

New technology being developed by researchers is using artificial intelligence to help detect melanoma skin cancer earlier…

skin

New technology being developed by researchers is using artificial intelligence (AI) to help detect melanoma skin cancer earlier.

The technology employs machine-learning software to analyse images of skin lesions and provide doctors with objective data on tell-tale biomarkers of melanoma, which is deadly if detected too late, but highly treatable if caught early.

The AI system–trained using tens of thousands of skin images and their corresponding eumelanin and haemoglobin levels–could initially reduce the number of unnecessary biopsies, a significant health-care cost. It gives doctors objective information on lesion characteristics to help them rule out melanoma before taking more invasive action. The technology could be available to doctors as early as next year.

 

access your free copy

 


Biomarkers are redefining how precision therapies are discovered, validated and delivered. 

This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Inside the report:

  • How leading organisations are reshaping strategy with biomarker-led approaches
  • Better tools for real-time decision-making – turning complex data into faster insights
  • Global standardisation and assay sensitivity – what it takes to scale across networks

Discover how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – access your free copy today

 

“This could be a very powerful tool for skin cancer clinical decision support,” said Alexander Wong, Professor of Systems Design & Engineering at Waterloo. “The more interpretable information there is, the better the decisions are.”

Currently, dermatologists largely rely on subjective visual examinations of skin lesions such as moles to decide if patients should undergo biopsies to diagnose the disease.

The new system deciphers levels of biomarker substances in lesions, adding consistent, quantitative information to assessments currently based on appearance alone. In particular, changes in the concentration and distribution of eumelanin, a chemical that gives skin its colour, and haemoglobin, a protein in red blood cells, are strong indicators of melanoma.

“There can be a huge lag time before doctors even figure out what is going on with the patient,” said Prof Wong. “Our goal is to shorten that process.”

 

Related topics
,

Related conditions

Related organisations

Leave a Reply

Your email address will not be published. Required fields are marked *